Communiqués Xencor, Inc.

Actions

XNCR

US98401F1057

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 18/08/2026			Varia. 5j.	Varia. 1 janv.
25,41 ^USD	+9,90%		+14,98%	+65,97%

06/08	Xencor, Inc. : RBC Capital Markets favorable sur le dossier	ZM
06/08	Xencor, Inc. : Wedbush à l'achat	ZM

Communiqués

05/08	Xencor: Q2 Earnings Snapshot	AQ
05/08	Xencor Reports Second Quarter 2026 Financial Results	BU
30/07	Xencor to Receive $105 Million from Alexion to Resolve Ultomiris U.S. Royalty Matter	AQ
29/07	Xencor to Receive $105 Million From Alexion to Resolve Ultomiris® U.S. Royalty Matter	BU
21/07	Practical Guidance For Pharmaceutical Method-of-Use Patent Claims After Teva v. Eli Lilly And In Re Xencor	AQ
17/07	Xencor Announces Proffered Paper Oral Presentation at ESMO 2026 for Phase 1 Clinical Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma	BU
06/05	Xencor: Q1 Earnings Snapshot	AQ
06/05	Xencor Reports First Quarter 2026 Financial Results	BU
04/05	Xencor to Host Webcast to Discuss XmAb942 and XmAb412 Data Presentations at DDW	BU
04/03	Xencor Announces Change to Ultomiris® Royalty Revenue Forecast	BU
25/02	Xencor: Q4 Earnings Snapshot	AQ
25/02	Xencor Reports Fourth Quarter and Full Year 2025 Financial Results	BU
23/02	Xencor to Participate at Upcoming Investor Conferences	BU
08/01	Xencor Highlights Corporate Priorities and 2026 Pipeline Milestones	BU
09/12	Xencor Announces Extension of U.S. Patent Term on Certain Xtend™ Antibodies	BU
10/11	Xencor to Participate at Upcoming Investor Conferences	BU
05/11	Xencor: Q3 Earnings Snapshot	AQ
05/11	Xencor Reports Third Quarter 2025 Financial Results	BU
27/10/25	Xencor Presents Initial Data for XmAb819, a First-in-class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Clear Cell Renal Cell Carcinoma	AQ
24/10/25	Xencor Presents Initial Data for XmAb819, a First-in-class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Clear Cell Renal Cell Carcinoma	BU
21/10/25	Xencor to Host Webcast and Conference Call to Discuss Initial Results from the Ongoing Phase 1 Dose-Escalation Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma	BU
14/10/25	Xencor Announces Presentation of Initial Phase 1 Dose-Escalation Results of XmAb819 in Clear Cell Renal Cell Carcinoma at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics	BU
27/08/25	Xencor to Participate at Upcoming Investor Conferences	BU
06/08/25	Xencor: Q2 Earnings Snapshot	AQ
06/08/25	Xencor Reports Second Quarter 2025 Financial Results	BU